



04 April 2009

Ms Kate Kidson
Principal Adviser, Issuers
ASX Limited
Level 45
South Tower
Stock Exchange Centre
525 Collins St
Melbourne Vic 3000

Dear Ms Kidson,

On April 30, 2009 the Company forwarded to the ASX an updated Appendix 3Y concerning the Change of Director's Interest of Dr Geoff Brooke following acquisition of shares as part of a recently-completed placement.

This notification incorrectly indicated that the date of change was April 28, 2008. The correct date was April 28, 2009.

An updated Appendix 3Y is attached.

Yours faithfully

A handwritten signature in black ink, appearing to read "J. A. Campbell", written over a light blue horizontal line.

J. A. Campbell
Company Secretary

Unlisted options issued to a related party *Rule 3.19A.2*

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity; CHEMGENEX PHARMACEUTICALS LIMITED
ABN 79 000 248 304

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Geoff Brooke
Date of last notice	March 27, 2008

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2,325,581 ordinary fully paid shares (CXS), allotted to GBS Venture Partners as part of placement announced on April 9, 2009.
Date of change	April 28, 2009
No. of direct securities held prior to change	Nil
Class	Ordinary fully paid shares
Number acquired	2,325,581
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Allotment at 43 cents per share for total consideration of \$999,999.96
No. of securities held after change	250,000 unlisted options plus 20,779,464 ordinary fully paid shares (CXS), and 2,736,065 listed options (CXSOA) exercisable at \$0.68 held by GBS Venture Partners

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Part of placement of 23,255,814 ordinary shares at 43 cents each.</p>
--	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A
Interest disposed	N/A
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A
Interest after change	N/A



J. A. Campbell
 Company Secretary
 May 4, 2009

+ See chapter 19 for defined terms.